Efficacy of PI3K inhibitors to PI3K mutants in enzyme and cell levels

被引：0
|
作者：
Dan, Shingo [1 ]
Sugita, Hironobu [1 ]
Yamazaki, Kanami [1 ]
Yamori, Takao [1 ]
机构：
[1] Japanese Fdn Canc Res, Tokyo, Japan
来源：
CANCER RESEARCH | 2009年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-214
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Novel inhibitors of the PI3K family
    Carnero, Amancio
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (09) : 1265 - 1277
  • [22] Cardiovascular toxicity of PI3Kα inhibitors
    Sadasivan, Chandu
    Zhabyeyev, Pavel
    Labib, Dina
    White, James A.
    Paterson, D. Ian
    Oudit, Gavin Y.
    CLINICAL SCIENCE, 2020, 134 (19) : 2595 - 2622
  • [23] PI3Kα Inhibitors That Inhibit Metastasis
    Schmidt-Kittler, Oleg
    Zhu, Jiuxiang
    Yang, Jian
    Liu, Guosheng
    Hendricks, William
    Lengauer, Christoph
    Gabelli, Sandra B.
    Kinzler, Kenneth W.
    Vogelstein, Bert
    Huso, David L.
    Zhou, Shibin
    ONCOTARGET, 2010, 1 (05) : 339 - 348
  • [24] PI3K inhibitors in haematological malignancies
    Benjamin, David J.
    Prasad, Vinay
    LANCET ONCOLOGY, 2022, 23 (08): : E362 - E363
  • [25] The development of inhibitors of PI3K and Akt
    Dennis, PA
    ANNALS OF ONCOLOGY, 2006, 17 : 24 - 24
  • [26] Clinical development of inhibitors of the PI3K
    Saura Manich, C.
    CANCER RESEARCH, 2019, 79 (04)
  • [27] PI3Kα and PI3Kβ Have Distinct Roles in Rodent and Human β-Cell Function
    Kolic, Jelena
    Plummer, Gregory
    Leung, Eric
    Fox, Jocelyn E. Manning
    Macdonald, Patrick E.
    DIABETES, 2011, 60 : A97 - A97
  • [28] Taking PI3Kδ and PI3Kγ One Step Ahead: Dual Active PI3Kδ/γ Inhibitors for the Treatment of Immune-Mediated Inflammatory Diseases
    Rommel, Christian
    PHOSPHOINOSITIDE 3-KINASE IN HEALTH AND DISEASE, VOL 1, 2010, 346 : 279 - 299
  • [29] Predictive and pharmacodynamic (PD) markers of PI3K pathway inhibitors: focus on PI3K, AKT and mTOR inhibitors
    Tabernero, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S6 - S6
  • [30] Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors
    Rewcastle, Gordon W.
    Kolekar, Sharada
    Buchanan, Christina M.
    Gamage, Swarna A.
    Giddens, Anna C.
    Tsang, Kit Y.
    Kendall, Jackie D.
    Singh, Ripudaman
    Lee, Woo-Jeong
    Smith, Greg C.
    Han, Weiping
    Matthews, David J.
    Denny, William A.
    Shepherd, Peter R.
    Jamieson, Stephen M. F.
    ONCOTARGET, 2017, 8 (29) : 47725 - 47740
12345